These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20644626)

  • 1. Treatment of hepatitis C in children: a systematic review.
    Hu J; Doucette K; Hartling L; Tjosvold L; Robinson J
    PLoS One; 2010 Jul; 5(7):e11542. PubMed ID: 20644626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
    Devaki P; Jencks D; Yee BE; Nguyen MH
    Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
    Liu CH; Liu CJ; Lin CL; Liang CC; Hsu SJ; Yang SS; Hsu CS; Tseng TC; Wang CC; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2008 Nov; 47(10):1260-9. PubMed ID: 18834319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for dialysis patients with hepatitis C virus (HCV) infection.
    Prabhu RA; Nair S; Pai G; Reddy NP; Suvarna D
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007003. PubMed ID: 26287983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.
    Schwarz KB; Gonzalez-Peralta RP; Murray KF; Molleston JP; Haber BA; Jonas MM; Rosenthal P; Mohan P; Balistreri WF; Narkewicz MR; Smith L; Lobritto SJ; Rossi S; Valsamakis A; Goodman Z; Robuck PR; Barton BA;
    Gastroenterology; 2011 Feb; 140(2):450-458.e1. PubMed ID: 21036173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
    Niederau C; Mauss S; Böker K; Lutz T; Heyne R; Moog G; John C; Witthöft T; Alshuth U; Hüppe D
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.
    Xirouchakis E; Triantos C; Manousou P; Sigalas A; Calvaruso V; Corbani A; Leandro G; Patch D; Burroughs A
    J Viral Hepat; 2008 Oct; 15(10):699-709. PubMed ID: 18673428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.
    Malone DC; Tran TT; Poordad FF
    J Manag Care Pharm; 2005 Oct; 11(8):687-94. PubMed ID: 16194133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.
    Osaki R; Nishimura T; Shioya M; Takeuchi T; Okumura Y; Nakahara T; Bamba S; Nakajo S; Fujiyama Y; Andoh A
    Mol Med Rep; 2012 Feb; 5(2):525-8. PubMed ID: 22052088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological interventions for acute hepatitis C infection.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011644. PubMed ID: 30521693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.
    Gordon CE; Uhlig K; Lau J; Schmid CH; Levey AS; Wong JB
    Am J Kidney Dis; 2008 Feb; 51(2):263-77. PubMed ID: 18215704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.